Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Michael Amoroso is recorded as Chairman, Board Member, CEO and COO at Abeona Therapeutics Inc. (ABEO). Abeona Therapeutics Inc. reported in an 8-K filed June 12, 2026 that Michael Amoroso resigned as member of the Board of Directors, effective June 11, 2026. Abeona Therapeutics Inc. reported in an 8-K filed April 11, 2023 that Michael Amoroso was appointed Chairman of the Board, effective April 6, 2023. The proxy statement of Abeona Therapeutics Inc. reports total compensation of $1,499,160 for Michael Amoroso in fiscal 2020, including a base salary of $219,071. Michael Amoroso has spoken on 4 earnings calls across 1 company, most recently for Abeona Therapeutics Inc. on July 28, 2021.
“On June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the "Board") of Abeona Therapeutics Inc. (the "Company") effective immediately.”
“Also on April 6, 2023, Michael Amoroso, Chairman of the Board, relinquished his seat as a Class 2 director and was immediately appointed as a Class 1 director by the Board to stand for reelection at the 2023 Annual Shareholder Meeting.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2023-04-06–present
2021-03-19–present
2020-11-01–present
Source not stated
Start not stated–present
Start not stated–2026-06-11
Start not stated–2026-06-11
Start not stated–2021-10-14
Recorded roles and call appearances connecting this person to public companies.
Chairman, Board Member, CEO, COO
2020-11-01–present
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2020 | Abeona Therapeutics Inc. (ABEO) | Former President and Chief Executive Officer Fair value of option awards is calculated under ASC 718 as of the grant date using the Black-Scholes option-pricing model and as of the repricing date using a Hull-White I lattice model. Employees are assumed to exercise their options. The determination of the fair value of share-based payment awards made on the date of grant is affected by our Common Stock price as well as assumptions regarding a number of complex and subjective variables. Our assumptions in determining fair value are described in Note 11 of Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report. | $219,071 | $1,499,160 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
